| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2018-03-01 |
| タイトル |
|
|
タイトル |
Anti-cancer stem cell activity of the Src inhibitor dasatinib in thyroid cancer cells |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
OHTA, Yusuke
KOIKE, Yoshikazu
SAITOH, Wataru
YAMASHITA, Tetsumasa
TANAKA, Katsuhiro
KANOMATA, Naoki
MORIYA, Takuya
KUREBAYASHI, Junichi
|
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Breast and Thyroid Surgery, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Breast and Thyroid Surgery, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Breast and Thyroid Surgery, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Breast and Thyroid Surgery, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Breast and Thyroid Surgery, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Pathology 2, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Pathology 2, Kawasaki Medical School |
| 著者所属(英) |
|
|
言語 |
en |
|
値 |
Department of Breast and Thyroid Surgery, Kawasaki Medical School |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Dasatinib |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Src inhibitor |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Thyroid cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Anaplastic thyroid cancer |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cancer stem cells |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Paclitaxel |
| 抄録(英) |
|
|
言語 |
en |
|
値 |
Although the prognosis of differentiated thyroid cancer (DTC) is good, those of poorly-differentiated and undifferentiated thyroid cancers (PDTC and UDTC) are poor. Recent preclinical studies have suggested that the Src inhibitor dasatinib is active in thyroid cancer cell lines. We conducted the present study in an attempt to clarify the antitumor activity of dasatinib in PDTC and UDTC. The expression levels of c-Src, phosphorylated Srcs (p-SrcY416 and p-SrcY527), focal adhesion kinase (FAK), and phosphorylated FAK (p-FAKY861) were immunohistochemically investigated in a case-control series (15 cases of PDTC or UDTC vs. 29 control cases of DTC). The PDTC cell line KTC-1 and UDTC cell line KTC-2 were used to investigate the anticell growth and anti-cancer stem cell (CSC) activities of dasatinib. The combined effects of dasatinib and the taxane paclitaxel on anti-cell growth and anti-CSC activities were also tested. c-Src and p-FAKY861 expression levels were significantly higher, while those of p-SrcY416 were slightly higher in PDTC and UDTC than in DTC. Dasatinib inhibited cell growth in association with G1-S cell cycle retardation and increased apoptosis in both cell lines. Dasatinib significantly decreased the proportion of CSCs and more than additively enhanced the anti-cell growth activity of paclitaxel. The results of this study suggest that the Src signaling pathway is activated more in PDTC and UDTC than in DTC. The Src inhibitor dasatinib exhibited anti-cell growth and anti-CSC activities. Furthermore, it more than additively enhanced the anti-cell growth activity of paclitaxel. |
| 書誌情報 |
en : Kawasaki medical journal
巻 43,
号 2,
p. 63-78,
発行日 2017
|
| 出版者 |
|
|
出版者 |
Kawasaki Medical Society |
|
言語 |
en |
| ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
0385-0234 |
| ISSN |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
2434-3404 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12685295 |
| 書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12029005 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
https://doi.org/10.11482/KMJ-E43(2)63 |
| 記事種別(英) |
|
|
内容記述 |
Regular Article |
|
言語 |
en |
| 関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://igakkai.kms-igakkai.com/wp/wp-content/uploads/2017en/KMJ-E43(2)63.pdf |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
PDF (1.2 MB)
